/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

DiaMedica Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$8.61 0.0664(6.64%) DMAC at 04 Dec 2025 04:29 PM Biotechnology
Lowest Today 8.045
Highest Today 8.59
Today’s Open 8.045
Prev. Close 7.98
52 Week High 9.23
52 Week Low 3.19
Day’s Range: Low 8.045 High 8.59
52-Week Range: Low 3.19 High 9.23
1 day return -
1 Week return -1.33
1 month return +27.08
3 month return +57.83
6 month return +102.73
1 year return +55.38
3 year return +555.0
5 year return +50.17
10 year return -

Institutional Holdings

Cooperman Leon G 3.19

Vanguard Group Inc 2.97

BlackRock Inc 2.31

Vanguard Total Stock Mkt Idx Inv 1.62

PARAGON Assoc & PARAGON Assoc II JV 1.26

Geode Capital Management, LLC 1.22

First Manhattan Co. LLC 1.17

iShares Russell 2000 ETF 0.88

Bleichroeder LP 0.74

Northern Trust Corp 0.63

Vanguard Institutional Extnd Mkt Idx Tr 0.59

Fidelity Small Cap Index 0.51

State Street Corp 0.49

iShares Russell 2000 Growth ETF 0.47

Morgan Stanley - Brokerage Accounts 0.47

LPL Financial Corp 0.38

Advisor Group Holdings, Inc. 0.28

Fidelity Extended Market Index 0.27

Vanguard Russell 2000 ETF 0.25

State St Russell Sm Cap® Indx SL Cl I 0.18

Jacob Discovery Fd Instl 0.17

Charles Schwab Investment Management Inc 0.15

Royal Bank of Canada 0.15

Ronald Blue Trust, Inc. 0.13

Schwab Small Cap Index 0.13

NT R2000 Index Fund - NL 0.12

Marshall Wace Asset Management Ltd 0.12

iShares Micro-Cap ETF 0.12

Bank of New York Mellon Corp 0.12

Perigon Wealth Management, LLC 0.10

NT R2000 Index Fund - DC - NL - 3 0.10

Barclays PLC 0.09

Fidelity Total Market Index 0.09

iShares Russell 2000 Small-Cap Idx Instl 0.09

Fidelity Nasdaq Composite Index 0.08

Russell 2500™ Index Fund F 0.08

CATALYST FINANCIAL PARTNERS LLC 0.07

Extended Equity Market Fund K 0.07

Fidelity Series Total Market Index 0.07

Nuveen Small Cap Blend Idx R6 0.07

Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 415.58 M

PB Ratio 8.2623

PE Ratio 0.0

Enterprise Value 371.46 M

Total Assets 46.35 M

Volume 337840

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-17971000 -18.0M, FY22:-13676000 -13.7M, FY21:-13592000 -13.6M, FY20:-12292000 -12.3M, FY19:-10649000 -10.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-18000 -0.0M, Q2/2025:-3000 -0.0M, Q1/2025:-11000 -0.0M, Q3/2024:-6883000 -6.9M, Q2/2024:-10000 -0.0M

Quarterly Net worth Q3/2025:-8620000 -8.6M, Q2/2025:-7699000 -7.7M, Q1/2025:-7707000 -7.7M, Q3/2024:-6274000 -6.3M, Q2/2024:-5119000 -5.1M

Fund house & investment objective

Company Information DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Organisation Biotechnology

Employees 27

Industry Biotechnology

CEO Mr. Dietrich John Pauls MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow